Cargando…

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

A prominent mechanism of acquired resistance to BRAF inhibitors in BRAF(V600)-mutant melanoma is associated with the upregulation of receptor tyrosine kinases. Evidences suggested that this resistance mechanism is part of a more complex cellular adaptation process. Using an integrative strategy, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Titz, Bjoern, Lomova, Anastasia, Le, Allison, Hugo, Willy, Kong, Xiangju, ten Hoeve, Johanna, Friedman, Michael, Shi, Hubing, Moriceau, Gatien, Song, Chunying, Hong, Aayoung, Atefi, Mohammad, Li, Richard, Komisopoulou, Evangelia, Ribas, Antoni, Lo, Roger S, Graeber, Thomas G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012007/ https://www.ncbi.nlm.nih.gov/pubmed/27648299 http://dx.doi.org/10.1038/celldisc.2016.28

Ejemplares similares

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
por: Poulikakos, Poulikos I., et al.
Publicado: (2011)

CRAF R391W is a melanoma driver oncogene
por: Atefi, Mohammad, et al.
Publicado: (2016)

Phosphoproteomic Analysis of Platelets Activated by Pro-Thrombotic Oxidized Phospholipids and Thrombin
por: Zimman, Alejandro, et al.
Publicado: (2014)

Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
por: Dharanipragada, Prashanthi, et al.
Publicado: (2023)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Melanoma whole exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
por: Shi, Hubing, et al.
Publicado: (2012)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death
por: Graham, Nicholas A, et al.
Publicado: (2012)

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition
por: Mok, Stephen, et al.
Publicado: (2015)

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors
por: Escuin-Ordinas, Helena, et al.
Publicado: (2016)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

SPRED1 deletion confers resistance to MAPK inhibition in melanoma
por: Ablain, Julien, et al.
Publicado: (2020)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors
por: Delmas, Audrey, et al.
Publicado: (2015)

Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
por: Escuin-Ordinas, Helena, et al.
Publicado: (2021)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
por: Wang, Xueyan, et al.
Publicado: (2022)

Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures
por: Graham, Nicholas A, et al.
Publicado: (2017)

MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy
por: Liu, Philip T., et al.
Publicado: (2012)

Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models
por: Gobin, Bérengère, et al.
Publicado: (2014)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
por: Gentilcore, Giusy, et al.
Publicado: (2013)

Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance
por: Yang, Zhentao, et al.
Publicado: (2022)

Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
por: Lacouture, Mario E., et al.
Publicado: (2021)

HTLV-3 and HTLV-4 antisense proteins activate JunB-, c-Jun- and JunD-dependent transcription
por: Larocque, Émilie, et al.
Publicado: (2011)

JunB: a paradigm for Jun family in immune response and cancer
por: Ren, Fu-jia, et al.
Publicado: (2023)

Activation of c-Jun N-Terminal Kinase (JNK) during Mitosis in Retinal Progenitor Cells
por: Ribas, Vinicius Toledo, et al.
Publicado: (2012)

Selection and Characterization of a DNA Aptamer That Can Discriminate between cJun/cJun and cJun/cFos
por: Walters, Ryan D., et al.
Publicado: (2014)

Systematic analysis of BRAF(V)(600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis
por: Fallahi-Sichani, Mohammad, et al.
Publicado: (2015)

Aristarchus, Jun. in Explanation
por: Aristarchus,
Publicado: (1802)

The sterol regulatory element binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity
por: Kidani, Yoko, et al.
Publicado: (2013)

The Jun-dependent axon regeneration gene program: Jun promotes regeneration over plasticity
por: Mason, Matthew R J, et al.
Publicado: (2021)

Boning up on JunB
por: Dove, Alan W.
Publicado: (2004)

Navalis, Jun. on Burns and Scalds
por: Navalis,
Publicado: (1801)

Heo Jun: physician of the people
por: Kwon, Hyuk Joon
Publicado: (2021)

Oncogenic BRAF(V600E) induces microglial proliferation through extracellular signal-regulated kinase and neuronal death through c-Jun N-terminal kinase
por: Ye, Qing, et al.
Publicado: (2022)

ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
por: Fattore, Luigi, et al.
Publicado: (2015)

Erratum to: The Jun-dependent axon regeneration gene program: Jun promotes regeneration over plasticity
por: Mason, Matthew R J, et al.
Publicado: (2022)

JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer
por: Ruiz, E. Josue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sfhjd55t6qdla1atppgkksj2ps